, Decision_act (EU) 1998/251

In forcesince 21 May 1997

Germany's Boehringer Ingelheim and the Danish firm Novo Nordisk have entered into a multiyear agreement on research into drug treatment for obesity. The focus of the agreement will be the discovery of new drugs which influence receptors on cells in the brain or in fat cells, thereby regulating food intake, energy expenditure or the number of fat cells, and thus decreasing fat accumulation in obese people.

Ciba-Geigy (Basle, Switzerland) and Synaptic Pharmaceutical (Paramus, New Jersey, USA) have found a new Neuropeptide Y (NPY) receptor, (Y5). The peptide is produced in the brain and is important in regulating appetite, being the most potent appetite stimulant yet described. New treatments to fight obesity will be targeted at the receptor for NPY. Synaptic and Ciba-Geigy are engaged in preclinical research on various small-molecule compounds specific for the Y5 receptor. The first drug targeting Neuropeptide Y (NPY1), developed in a collaboration between Neurogen and Pfizer, has begun first-phase clinical trials on humans.

In the United States alone, customers paid as much as ECU 43 billion for weight-loss products such as special diets and over-the-counter medications, even though the results are short-term effects in most cases. Indeed, Redux, the first anti-obesity drug to be approved by the Food and Drug Administration in May 1996 is expected by some market analysts to generate peak annual sales of about ECU 430 million. Given the enormous market potential of anti-obesity drugs, it is not surprising that several companies are working in this highly competitive area, targeting a broad range of pharmacological pathways.

(b)

Development of Orlistat

The development of the anti-obesity drug Orlistat has followed the usual development path for pharmaceuticals:

Preclinical testing:

a company conducts laboratory and animal studies to show biological activity of the compound against the targeted ailment, and the compound is evaluated for safety. This phase may take from two to four years.

Clinical trials, phase I:

these tests involve about 20 to 80 normal, healthy volunteers and focus on drug safety and dosage, including studies of drug absorption, distribution in the body and drug metabolism.

Clinical trials, phase II:

studies with 100 to 300 volunteer patients to test the drug's effectiveness.

Clinical trials, phase III:

studies with 1 000 to 3 000 patients, usually in clinics and hospitals to determine drug efficacy and identify adverse reactions.